Literature DB >> 10747907

Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments.

T Maas1, J Eidenmüller, R Brandt.   

Abstract

The axonal microtubule-associated phosphoprotein tau interacts with neural plasma membrane (PM) components during neuronal development (Brandt, R., Léger, J., and Lee, G. (1995) J. Cell Biol. 131, 1327-1340). To analyze the mechanism and potential regulation of tau's PM association, a method was developed to isolate PM-associated tau using microsphere separation of surface-biotinylated cells. We show that tau's PM association requires an intact membrane cortex and that PM-associated tau and cytosolic tau are differentially phosphorylated at sites detected by several Alzheimer's disease (AD) diagnostic antibodies (Ser(199)/Ser(202), Thr(231), and Ser(396)/Ser(404)). In polar neurons, the association of endogenous tau phosphoisoforms with the membrane cortex correlates with an enrichment in the axonal compartment. To test for a direct effect of AD-specific tau modifications in determining tau's interactions, a phosphomutant that simulates an AD-like hyperphosphorylation of tau was produced by site-directed mutagenesis of Ser/Thr residues to negatively charged amino acids (Glu). These mutations completely abolish tau's association with the membrane cortex; however, the construct retains its capability to bind to microtubules. The data suggest that a loss of tau's association with the membrane cortex as a result of phosphorylation at sites that are modified during disease contributes to somatodendritic tau accumulation, axonal microtubule disintegration, and neuronal death characteristic for AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747907     DOI: 10.1074/jbc.M000389200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

2.  Administration of the benzodiazepine midazolam increases tau phosphorylation in the mouse brain.

Authors:  Robert A Whittington; László Virág; Maud Gratuze; Hilana Lewkowitz-Shpuntoff; Mehdi Cheheltanan; Franck Petry; Isabelle Poitras; Françoise Morin; Emmanuel Planel
Journal:  Neurobiol Aging       Date:  2018-11-08       Impact factor: 4.673

3.  Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease.

Authors:  Laura E Donovan; Lenora Higginbotham; Eric B Dammer; Marla Gearing; Howard D Rees; Qiangwei Xia; Duc M Duong; Nicholas T Seyfried; James J Lah; Allan I Levey
Journal:  Proteomics Clin Appl       Date:  2012-04       Impact factor: 3.494

4.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

5.  New insights into clinical trial for Colostrinin in Alzheimer's disease.

Authors:  P Szaniszlo; P German; G Hajas; D N Saenz; M Kruzel; I Boldogh
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

6.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

7.  CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation.

Authors:  Yazi D Ke; Gabriella Chan; Kristie Stefanoska; Carol Au; Mian Bi; Julius Müller; Magdalena Przybyla; Astrid Feiten; Emmanuel Prikas; Glenda M Halliday; Olivier Piguet; Matthew C Kiernan; Michael Kassiou; John R Hodges; Clement T Loy; John S Mattick; Arne Ittner; Jillian J Kril; Greg T Sutherland; Lars M Ittner
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 9.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 10.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.